We also observed that our risk signature was associated with tumor mutations and immune landscape, and that it is suitable for predicting the responsiveness of ESCC patients to immunotherapy targeting PD-L1 blockade. This evidence concerns the gene CD274 and esophageal squamous cell carcinoma.